68314-54-5

Basic information

• Product Name: 1-Bromo-2-(methoxymethoxy)benzene
• Synonyms: 1-Bromo-2-(methoxymethoxy)benzene
• CAS NO: 68314-54-5
• Molecular Formula: C₈H₉BrO₂
• Molecular Weight: 217.05986
• Mol File: 68314-54-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Bromo-2-(methoxymethoxy)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Bromo-2-(methoxymethoxy)benzene(68314-54-5)
• EPA Substance Registry System: 1-Bromo-2-(methoxymethoxy)benzene(68314-54-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 68314-54-5(Hazardous Substances Data)

Usage

Chemical Class

Benzene derivative

Appearance

Colorless to pale yellow liquid

Odor

Faint

Usage

Intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds

Bromine and methoxymethoxy groups

Makes it a versatile compound for various chemical reactions and applications

Hazardous nature

Potentially hazardous chemical, may cause skin and eye irritation upon contact.

Upstream product

• 824-91-9 O-methoxymethylphenol 
• 13057-17-5 bromethyl methyl ether 
• 1829-37-4 o-bromophenyl acetate 
• 109-87-5 Dimethoxymethane 
• 95-56-7 2-hydroxybromobenzene 
• 107-30-2 chloromethyl methyl ether 

Downstream Products

• 79237-23-3 (methoxymethylenoxy-2' phenyl)-3 cyclohexen-2 one 
• 1071206-15-9 (Z)-1-(2-ethoxyethenyl)-2-(methoxymethoxy)benzene 
• 68314-55-6 C₃₀H₃₂O₆P₂ 
• 618094-82-9 N-[2-(methoxymethoxy)phenyl]-N-[(1S)-1-phenylethyl]amine 
• 674309-58-1 2-(2-methoxymethoxy-phenyl)-cyclohex-3-ene-1,2-diol 
• 674309-59-2 2-(2-methoxymethoxy-phenyl)-cyclohept-3-ene-1,2-diol 
• 886054-90-6 3-(4-methoxymethoxy-3-{2-methoxy-4-[3-(2-methoxymethoxy-phenyl)-3-oxo-propyl]-phenoxy}-phenyl)-1-(2-methoxymethoxy-phenyl)-propan-1-one 
• 55568-97-3 (2R,3R)-3-hydroxyflavanone 
• 126412-19-9 (methoxymethylenoxy-2' phenyl)-3 formyl-6 cyclohexen-2 one 
• 126412-21-3 (methoxymethylenoxy-2' phenyl)-3 (dithio-1,3 propyl)-6 cyclohexen-2 ol 
• 126412-20-2 (methoxymethylenoxy-2' phenyl)-3 (dithio-1,3 propyl)-6 cyclohexen-2 one 
• 126412-27-9 (methoxymethylenoxy-2' fluoro-3' phenyl)-3 (dithio-1,3 propyl)-6 cyclohexen-2 ol 
• 126412-22-4 (methoxymethylenoxy-2' phenyl)-3 ((dithio-1,3 propyl)-6 cyclohexen-1 yl)-2 N,N dimethylacetamide 
• 126412-28-0 (methoxymethylenoxy-2' fluoro-3' phenyl)-3 ((dithio-1,3 propyl)-6 cyclohexen-1 yl)-2 N,N dimethylacetamide 

Relevant articles and documents

A study of enantioselective syntheses by Sharpless asymmetric oxidation for aryl sulfoxides containing oxygen groups at the ortho position

Abstract: While ortho-alkoxy aryl sulfoxides including various substituents were synthesized by Sharpless asymmetric oxidation reaction, we optimized the reaction conditions and screened better combination of starting materials to obtain high enantioselectivity. The result suggested new information that electron-withdrawing substituents on the aromatic ring have a strong influence upon enantioselectivity of the products. Also, several chiral ligands for Sharpless asymmetric oxidation reaction were evaluated to improve the enantioselectivity. Graphic abstract: High enantioselectivity of ortho-alkoxy aryl chiral sulfoxides have been achieved by Sharpless oxidation reaction using Ti(O-i-Pr)4 and diethyl tartrate under anhydrous condition. In particular, the enantioselctivity of products was influenced by electron-withdrawing substituents on the aromatic ring, such as nitro, ester and aldehyde groups.[Figure not available: see fulltext.]

TARGETED BIFUNCTIONAL DEGRADERS

The present invention provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In another aspect, the present invention provides bifunctional compounds that can be used to promote or enhance degradation of certain autoantibodies. In certain embodiments, treatment or management of a disease and/or disorder requires degradation, removal, or reduction in concentration of the circulating protein or the autoantibody in the subject. Thus, in certain embodiments, administration of a compound of the invention to the subject removes or reduces the circulation concentration of the circulating protein or the autoantibody, thus treating, ameliorating, or preventing the disease and/or disorder. In certain embodiments, the circulating protein is TNF.

Giving a Second Chance to Ir/Sulfoximine-Based Catalysts for the Asymmetric Hydrogenation of Olefins Containing Poorly Coordinative Groups

This work identifies a family of Ir/phosphite-sulfoximine catalysts that has been successfully used in the asymmetric hydrogenation of olefins with poorly coordinative or noncoordinative groups. In comparison with analogue Ir/phosphine-sulfoximine catalysts previously reported, the presence of a phosphite group extended the range of olefins than can be efficiently hydrogenated. High enantioselectivities, comparable to the best ones reported, have been achieved for a wide range of olefins containing relevant poorly coordinative groups such as α,β-unsaturated enones, esters, lactones, and lactams as well as alkenylboronic esters.

A Copper-Mediated Conjugate Addition Approach to Analogues of Aconitine-Type Diterpenoid Alkaloids

A copper-mediated conjugate addition of electron-rich aryl groups into a complex vinyl nitrile using arylmagnesium bromides is reported. The conjugate addition adducts were advanced toward the synthesis of designed aconitine-type analogues. The variation

Design, synthesis, and evaluation of A-ring-modified lamellarin N analogues as noncovalent inhibitors of the EGFR T790M/L858R mutant

A series of A-ring-modified lamellarin N analogues were designed, synthesized, and evaluated as potential noncovalent inhibitors of the EGFR T790M/L858R mutant, a causal factor in the drug-resistant non-small cell lung cancer. Several water-soluble ammonium- or guanidinium-tethered analogues exhibited good kinase inhibitory activities. The most promising analogue, 14f, displayed an excellent inhibitory profile against the T790M/L858R mutant [IC50 (WT) = 31.8 nM; IC50 (T790M/L858R) = 8.9 nM]. The effects of A-ring-substituents on activity were rationalized by docking studies.

TRICYCLIC MODULATORS OF TNF SIGNALING

The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, prodrugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.

Two novel tetracycles, cassibiphenols A and B from the flowers of Cassia siamea

Chemical investigation of the flowers of Cassia siamea (Leguminosae), resulted in the isolation of two novel tetracycles connecting 5-(2-hydroxypropyl)benzene-1,3-diol, cassibiphenols A (1) and B (2). The structures were elucidated by analysis of the 1D, 2D NMR, and HRMS spectra. Synthesis of a tetracyclic core of 1 and 2 led to determine the absolute configuration of 1 and C-12 of 2.

Electrophilic C12 building blocks for alkaloids: 1,1 iterative organoiron-mediated routes to (±)-lycoramine and (±)-maritidine

Aryllithium reagents generated from protected 6-bromoguaiacol and 2-bromo-4,5-dimethoxybenzyl alcohol derivatives were used to prepare ortho-substituted (1-arylcyclohexadienyl)iron(1+) electrophiles. These were treated with Na+[Me3SiCH2CH2O 2CCHCN]- to build aryl-substituted quaternary centres in new examples of 1,1 iterative {[I·4] → [I·5]+ → [I·4] → [I·5]+ → [I· 4]} reaction sequences, which make use of the electrophilicity of the metal complex in two key carbon-carbon bond-formation steps. MOM protection of the guaiacol was better than SEM for access to the lycoramine skeleton, and TBDPS was best for maritidine. Decomplexation, hydrolysis, and cyclisation completed formal total syntheses of the Amaryllidaceae alkaloids (±)-lycoramine and (±)-marididine, establishing the compatibility of the organoiron method with the presence of ortho substituents on the aryl group, and nucleophile addition ipso to the substituted arene. Copyright

Hydrogen bonds in phenylboronic acids with polyoxaalkyl substituents at ortho-position

Phenylboronic acids with polyoxaalkyl substituents at ortho position were synthesized from the corresponding bromides. Structures in solid state, determined by single crystal X-ray diffraction, reveal the presence of inter- and intramolecular hydrogen bonds. Presence of several oxygen atoms in oxaalkyl chains enables the formation of intramolecular hydrogen bonds by B(OH)2 group with different oxygen centers which lead to the formation of bifurcated hydrogen bonds. Investigated compounds were characterized by 1H, 13C, 11B and 17O NMR spectroscopy in solution. Assignment of 1H and 13C signals was made on the basis of HSQC and HMBC spectra. 17O NMR spectra show that in acetonitrile solution hydrogen bonds with solvent molecules are predominant.

SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY

A sulfonamide derivative having DP receptor antagonistic activity; and a medicinal composition and a therapeutic agent for allergic diseases which each contains the compound as an active ingredient. The derivative is a compound represented by the general formula (II): (II) (wherein ring A is an aromatic carbocycle, etc.; ring B is a nitrogenous nonaromatic heterocycle, etc.; ring C is an aromatic carbocycle, etc.; R1 is carboxy, etc.; R2's each independently is halogeno, etc.; R3 is optionally substituted alkyloxy, etc.; R4's each independently is halogeno, etc.; R5's each independently is optionally substituted alkyl, etc.; M is sulfonyl, etc.; Y is a single bond, etc.; L1 is a single bond, etc.; L2 is a single bond, etc.; k is 0, 1, 2, 3, or 4; n is 0, 1, or 2; and q is 0, 1, 2, or 3, provided that, for example, a) when ring B is a 6-membered nitrogenous heterocycle containing one or two nitrogen atoms and ring C is a benzene ring, then k is not 0), a pharmaceutically acceptable salt of the compound, or a hydrate of either.